Cargando…
Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai
BACKGROUND: Shenxian-Shengmai (SXSM) Oral Liquid is a CFDA-approved patent Chinese Herbal medicine, which has been clinically used for the treatment of bradycardia. However, its active components and action mechanism remain to be established. The present study aimed to evaluate the efficacy of SXSM...
Autores principales: | Gao, Jiaming, Wang, Taiyi, Yao, Xi, Xie, Weiwei, Shi, Xianru, He, Shuang, Zhao, Tao, Wang, Chunhua, Zhu, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902583/ https://www.ncbi.nlm.nih.gov/pubmed/31822281 http://dx.doi.org/10.1186/s12906-019-2769-0 |
Ejemplares similares
-
Shenxian-Shengmai Oral Liquid Improves Sinoatrial Node Dysfunction through the PKC/NOX-2 Signaling Pathway
por: Zhang, Heng, et al.
Publicado: (2021) -
Shenxian-Shengmai Oral Liquid Evoke Autophagy of Fibroblast to Attenuate Sinoatrial Node Fibrosis in Sick Sinus Syndrome Mice via the AKT/mTOR Pathway
por: Chen, Chen, et al.
Publicado: (2022) -
Investigation of the Mechanism of Shengmai Injection on Sepsis by Network Pharmacology Approaches
por: Lu, Juan, et al.
Publicado: (2020) -
Exploring the mechanism of Shengmai Yin for coronary heart disease based on systematic pharmacology and chemoinformatics
por: Jiang, Yan, et al.
Publicado: (2020) -
Prediction the Molecular Mechanism of Shengmai Injection in Acute Treatment of COVID-19 Based on Network Pharmacology
por: Wang, Chen, et al.
Publicado: (2022)